Effect of beta-blockers and angiotensin receptor blockers in reducing the aortic growth rate in children with bicuspid aortic valve-related aortopathy

Emanuele Monda,Antonella Boccia,Ippolita Altobelli,Alfredo Mauriello,Gianantonio De Michele,Sabrina Siniscalchi,Adelaide Fusco,Annapaola Cirillo,Marta Rubino,Federica Verrillo,Gaetano Diana,Chiara Cirillo,Martina Caiazza,Eduardo Bossone,Alessandro Della Corte,Maria Giovanna Russo,Giuseppe Limongelli
DOI: https://doi.org/10.1016/j.ijcard.2024.132067
IF: 4.039
2024-05-08
International Journal of Cardiology
Abstract:Aims The aim of this study is to evaluate the effect of beta-blockers and angiotensin receptor blockers in reducing the aortic growth rate in children with bicuspid aortic valve (BAV)-related aortopathy and ascending phenotype. Methods Consecutive paediatric patients (≤16 years) with BAV and ascending aorta (AsAo) dilation (z-score > 3) were enrolled in this observational retrospective cohort study. Patients receiving prophylactic treatment with either atenolol (0.5 to 1.0 mg/kg/daily) or losartan (0.7 to 1.4 mg/kg/daily) were compared with those who did not receive medical prophylaxis (control group). The primary outcome of interest was the annual rate of change in maximal AsAo diameter z-score in the treatment and control groups. Results From a cohort of 1005 patients, 120 (mean age 11.3 ± 4.5 years, 82% males) fulfilled the inclusion criteria and were included in the study. Patients in the treatment and control group had similar age, sex, family history of BAV, BAV morphology, and baseline AsAo diameter. During a median follow-up of 7.1 years (interquartile range 3.8–10.2), no differences were observed in the annual growth rate of aortic diameter z-score between patients on treatment and controls. The prevalence of aortic diameter progression was similar in the treatment and control groups, and treatment with atenolol or losartan was not associated with a lower rate of aortic disease progression. Conclusions The findings revealed no significant difference in the annual aortic growth rate between treated and untreated patients. Larger cohort studies or, ideally, randomized clinical controlled trials are needed to validate these findings.
cardiac & cardiovascular systems
What problem does this paper attempt to address?